The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer

被引:62
作者
Billingham, LJ [1 ]
Cullen, MH
机构
[1] Univ Birmingham, Sch Med, Inst Canc Studies, Canc Res Campaign,Trials Unit, Birmingham B15 2TT, W Midlands, England
[2] Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Ctr Canc, Birmingham, W Midlands, England
关键词
chemotherapy; non-small-cell lung cancer; performance status; subgroup analysis;
D O I
10.1023/A:1013582618920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cisplatin-based chemotherapy improves survival in advanced non-small-cell lung cancer. Using data from phase III trials of mitomycin, ifosfamide and cisplatin, this paper investigates whether the beneficial effect of chemotherapy on survival and quality of life seen overall is limited to certain patient subgroups. Patients and methods: The survival benefit of chemotherapy was compared with standard treatment using hazard ratios for subgroups specified by stage, sex, age, histology and performance status (PS). The effect on quality of life was investigated for three subgroups defined by performance status. Results: The overall unstratified hazard ratio for all 797 eligible patients shows a 16% reduction in the risk of death with chemotherapy (P = 0.02). This benefit was seen for both locally advanced and extensive stage disease (significantly in extensive disease). Subgroups defined by sex, age and histology consistently benefitted from chemotherapy. The hazard ratios for the three levels of performance status suggest that PS2 patients gain no survival benefit from chemotherapy. In contrast, these patients experienced the greatest improvement in quality of life during the first six weeks of chemotherapy. Conclusions: Subgroup analysis suggests that the prolongation of life from cisplatin-based chemotherapy is confined to PS0/1 patients. Palliation is greater in PS2 patients.
引用
收藏
页码:1671 / 1675
页数:5
相关论文
共 12 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]  
BULPITT CJ, 1988, LANCET, V2, P31
[4]   Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].
Cullen, MH ;
Billingham, LJ ;
Woodroffe, CM ;
Chetiyawardana, AD ;
Gower, NH ;
Joshi, R ;
Ferry, DR ;
Rudd, RM ;
Spiro, SG ;
Cook, JE ;
Trask, C ;
Bessell, E ;
Connolly, CK ;
Tobias, J ;
Souhami, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194
[5]   A RANDOMIZED TRIAL OF INDUCTION CHEMOTHERAPY PLUS HIGH-DOSE RADIATION VERSUS RADIATION ALONE IN STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
DILLMAN, RO ;
SEAGREN, SL ;
PROPERT, KJ ;
GUERRA, J ;
EATON, WL ;
PERRY, MC ;
CAREY, RW ;
FREI, EF ;
GREEN, MR .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :940-945
[6]  
*EARL BREAST TRIAL, 1990, TREATM EARL BREAST C, V1
[7]  
JOHNSON DH, 1999, P AN M AM SOC CLIN, V18, pA461
[8]  
KELLY K, 1999, P AN M AM SOC CLIN, V18, pA461
[9]   A CONSUMERS GUIDE TO SUBGROUP ANALYSES [J].
OXMAN, AD ;
GUYATT, GH .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :78-84
[10]   Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews [J].
Silvestri, G ;
Pritchard, R ;
Welch, HG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7161) :771-775